|
Cirrhosis, Familial
|
0.500 |
GeneticVariation
|
disease |
UNIPROT |
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies.
|
12724528 |
2003 |
|
Cirrhosis, Familial
|
0.500 |
GeneticVariation
|
disease |
UNIPROT |
Mutation of human keratin 18 in association with cryptogenic cirrhosis.
|
9011570 |
1997 |
|
Cirrhosis, Familial
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Further results demonstrated that CK18 stable knockdown using shRNA increased BCRP expression and induced the EMT process in human breast cancer MCF‑7 cells.
|
30896886 |
2019 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Taken together, the present study demonstrated that CK18 might be served as a novel biomarker to predict clinicopathological features and the outcome of breast cancer.
|
29437899 |
2018 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Dynamic dialog between cytokeratin 18 and annexin A1 in breast cancer: a transcriptional disequilibrium.
|
25028131 |
2014 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Therefore, our findings suggest that loss of KT18 expression might be a good indicator of the poor prognosis of the breast cancer and it may play an active role in the breast tumorigenesis.
|
22699783 |
2011 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
CTD_human |
Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
|
20061804 |
2010 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
We here evaluated the use of cytokeratin-18 (CK18) as a serum biomarker for monitoring chemotherapy-induced cell death in breast cancer.
|
17545523 |
2007 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
To confirm these observations, we transfected the human K18 gene into the human breast cancer cell line MDA-MB-231 and isolated a stable overexpressing clone.
|
16046547 |
2005 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
While CK-18 is a marker for epithelia in general, CEA is mainly employed in the detection of gastrointestinal and breast carcinomas.
|
7541767 |
1995 |
|
Malignant neoplasm of breast
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Further results demonstrated that CK18 stable knockdown using shRNA increased BCRP expression and induced the EMT process in human breast cancer MCF‑7 cells.
|
30896886 |
2019 |
|
Fibrosis, Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
|
30839434 |
2019 |
|
Fibrosis, Liver
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Thus, the aim of this research will be to evaluate the effect of supplementation with total anthocyanin-base standardized cornelian cherry fruit extract on liver function (Serum levels of Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), cytokeratin-18 fragment M30 (CK-18 M30), as well as steatosis and fibrosis of liver), tumor necrosis factor α (TNF-α), malondealdehyde (MDA), and adiponectin in patients with NAFLD.
|
31324181 |
2019 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
Taken together, the present study demonstrated that CK18 might be served as a novel biomarker to predict clinicopathological features and the outcome of breast cancer.
|
29437899 |
2018 |
|
Fibrosis, Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
|
29167192 |
2018 |
|
Fibrosis, Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
|
29308929 |
2018 |
|
Fibrosis, Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
In patients with NAFLD, CK-18 and NFS could be useful in predicting NASH and liver fibrosis, respectively.
|
28359548 |
2018 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
Dynamic dialog between cytokeratin 18 and annexin A1 in breast cancer: a transcriptional disequilibrium.
|
25028131 |
2014 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
CTD_human |
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
|
25330770 |
2014 |
|
Malignant neoplasm of breast
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Therefore, our findings suggest that loss of KT18 expression might be a good indicator of the poor prognosis of the breast cancer and it may play an active role in the breast tumorigenesis.
|
22699783 |
2011 |
|
Fibrosis, Liver
|
0.360 |
Biomarker
|
disease |
BEFREE |
Of the biomarkers, hyaluronic acid and cytokeratin-18 fragment testing show promise as markers of hepatic fibrosis and NASH, respectively.
|
21199528 |
2011 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
CTD_human |
Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
|
20061804 |
2010 |
|
Fibrosis, Liver
|
0.360 |
Therapeutic
|
disease |
CTD_human |
Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations.
|
20538000 |
2010 |